Voyager Therapeutics’ (VYGR) “Buy” Rating Reiterated at Piper Jaffray Cos.
Voyager Therapeutics Inc. (NASDAQ:VYGR)‘s stock had its “buy” rating reissued by stock analysts at Piper Jaffray Cos. in a report issued on Sunday. They presently have a $37.00 price target on the stock. Piper Jaffray Cos.’s price target points to a potential upside of 202.29% from the company’s previous close.
Other equities analysts have also issued reports about the company. Cowen and Company restated a “buy” rating on shares of Voyager Therapeutics in a research report on Thursday. Wedbush restated an “outperform” rating and set a $36.00 target price on shares of Voyager Therapeutics in a research report on Thursday. Finally, Zacks Investment Research lowered Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, October 26th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Voyager Therapeutics presently has an average rating of “Buy” and a consensus target price of $26.80.
Voyager Therapeutics (NASDAQ:VYGR) opened at 12.24 on Friday. Voyager Therapeutics has a 12-month low of $8.12 and a 12-month high of $30.54. The firm’s market cap is $327.15 million. The company has a 50-day moving average price of $12.15 and a 200-day moving average price of $12.92.
Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Thursday, August 11th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by $0.03. Voyager Therapeutics had a negative return on equity of 20.15% and a negative net margin of 195.31%. On average, analysts predict that Voyager Therapeutics will post ($1.48) earnings per share for the current year.
Several institutional investors have recently added to or reduced their stakes in VYGR. Bank of New York Mellon Corp boosted its position in Voyager Therapeutics by 0.3% in the third quarter. Bank of New York Mellon Corp now owns 33,365 shares of the company’s stock valued at $401,000 after buying an additional 90 shares during the period. California State Teachers Retirement System boosted its stake in Voyager Therapeutics by 0.8% in the third quarter. California State Teachers Retirement System now owns 24,811 shares of the company’s stock valued at $298,000 after buying an additional 200 shares during the last quarter. Wells Fargo & Company MN boosted its stake in Voyager Therapeutics by 41.5% in the third quarter. Wells Fargo & Company MN now owns 25,695 shares of the company’s stock valued at $309,000 after buying an additional 7,539 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its stake in Voyager Therapeutics by 52.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 26,281 shares of the company’s stock valued at $289,000 after buying an additional 9,010 shares during the last quarter. Finally, Strs Ohio boosted its stake in Voyager Therapeutics by 531.6% in the second quarter. Strs Ohio now owns 12,000 shares of the company’s stock valued at $131,000 after buying an additional 10,100 shares during the last quarter. Institutional investors and hedge funds own 39.65% of the company’s stock.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company is focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s product pipeline includes programs for Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer’s disease and severe, chronic pain.
Receive News & Stock Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related stocks with our FREE daily email newsletter.